Roch doliveux biography of barack

Paul Tunnah interviews Dr Roch Doliveux

UCB

Continuing our series speaking to senior executives who are transforming the pharma business model, pharmaphorum catches up with Dr Roch Doliveux, CEO of UCB, to find out what is the key to driving innovation as a patient-centric biopharmaceutical company.

The man at the helm of biopharmaceutical company UCB is in an ebullient mood following the release of the company’s full year results.¹ Revenue growth of 2% at constant exchange rates compared to may not seem exceptional at first glance (although many pharma companies are seeing flatter sales growth or even decline in the current economy), but the deeper story of how UCB is transforming its business is what excites its Chief Executive, Dr Roch Doliveux.

&nbsp,

"…the self-styled description of UCB as being ‘patient-centric’ goes far beyond just words"

&nbsp,

Speaking with Roch, it is clear that the Roch Doliveux – Advisor to the Board – UCB | LinkedIn XIP